Literature DB >> 33079470

The prognostic significance of the treatment response of regional lymph nodes and the refinement of the current TNM staging system in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.

Jian Cui1, Lin Zhang1, Lin Yang2, Yue-Lu Zhu2, Hui Fang3, Bo Chen3, Yi Ning4, Hai-Zeng Zhang1.   

Abstract

The current TNM staging system uses the same category definitions for both rectal cancer patients with and without neoadjuvant chemoradiotherapy (NCRT). However, ypTNM stage, especially ypN stage does not predict patient survival after NCRT well. Whether tumor regression in lymph nodes (LRG) may improve the prediction has not been well studied. In total, 358 patients with rectal cancer who received NCRT followed by radical resection were recruited from 2004 to 2015, and the median follow-up time was 57.5 months. The main outcome measure was disease-free survival (DFS). In univariate analysis, factors associated with DFS were ypT stage, ypN stage, number of negative lymph nodes (NLN), lymph node ratio (LNR), tumor regression grade (TRG), M-TTRG (modified ypT stage by combining ypT stage and TRG), maximum LRG (LRGmax), sum score of LRG (LRGsum), LRG ratio (average value of LRGsum), and M-NLRG (modified ypN stage by combining LRGmax and LNR). In the multivariate Cox regression analysis, M-TTRG and M-NLRG (p < 0.001 and p = 0.030, respectively) were significantly associated with DFS. The estimated 5-year DFS rates were 86.6%, 60.3%, and 36.4% for patients with M-NLRG-0, M-NLRG-1, and M-NLRG-2, respectively (p < 0.001). A significant difference in survival was observed among patients with NCRT after incorporating TRG and LRG simultaneously into the current ypTNM staging system (p < 0.001). LRG was an important prognostic factor in rectal cancer patients treated with NCRT and could refine the ypTNM staging system. The modified ypTNM staging system in combination with LRGmax, LNR, and TRG could improve the DFS prediction in each subset of patients.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  lymph node regression; neoadjuvant chemoradiotherapy; prognosis; rectal cancer; tumor regression grade

Mesh:

Year:  2020        PMID: 33079470      PMCID: PMC7774730          DOI: 10.1002/cam4.3553

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  21 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  [Surgical management of patients with pathologic complete response in the primary tumor after neoadjuvant chemotherapy for rectal cancer].

Authors:  Jian Cui; Lin Yang; Lei Guo; Yongfu Shao; Ni Li; Haizeng Zhang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2015-06

3.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

4.  Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy.

Authors:  Anand Govindarajan; Mithat Gönen; Martin R Weiser; Jinru Shia; Larissa K Temple; Jose G Guillem; Philip B Paty; Garrett M Nash
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

5.  Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centre.

Authors:  D Leonard; C Remue; N Abbes Orabi; A van Maanen; E Danse; A Dragean; D Debetancourt; Y Humblet; A Jouret-Mourin; F Maddalena; A Medina Benites; P Scalliet; C Sempoux; M Van den Eynde; J C De Schoutheete; A Kartheuser
Journal:  Colorectal Dis       Date:  2016-06       Impact factor: 3.788

6.  Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status.

Authors:  Jessica M Leers; Shahin Ayazi; Jeffrey A Hagen; Sergei Terterov; Nancy Klipfel; Arzu Oezcelik; Emmanuele Abate; John C Lipham; Steven R DeMeester; Farzaneh Banki; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2009-04       Impact factor: 6.113

7.  Prognostic significance of partial tumor regression after preoperative chemoradiotherapy for rectal cancer: a meta-analysis.

Authors:  Yen-Chien Lee; Chung-Cheng Hsieh; Jen-Pin Chuang
Journal:  Dis Colon Rectum       Date:  2013-09       Impact factor: 4.585

8.  Lymph node status as a prognostic indicator after preoperative neoadjuvant chemoradiotherapy of rectal cancer.

Authors:  N Mirbagheri; B Kumar; S Deb; B R Poh; J G Dark; C C Leow; W M K Teoh
Journal:  Colorectal Dis       Date:  2014-10       Impact factor: 3.788

9.  Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.

Authors:  Tae Hyun Kim; Hee Jin Chang; Dae Yong Kim; Kyung Hae Jung; Yong Sang Hong; Sun Young Kim; Ji Won Park; Jae Hwan Oh; Seok-Byung Lim; Hyo Seong Choi; Seung-Yong Jeong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-30       Impact factor: 7.038

10.  Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction.

Authors:  Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Kaori Shima; Yoshifumi Baba; Gregory J Kirkner; Mari Mino-Kenudson; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Am J Gastroenterol       Date:  2009-10-06       Impact factor: 10.864

View more
  2 in total

1.  Risk factors for long-term survival in patients with ypN+ M0 rectal cancer after radical anterior resection.

Authors:  Marcin Zeman; Władysław Skałba; Piotr Szymański; Grzegorz Hadasik; Dmytro Żaworonkow; Dominik A Walczak; Agnieszka Czarniecka
Journal:  BMC Gastroenterol       Date:  2022-03-26       Impact factor: 3.067

Review 2.  Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Authors:  Lei He; Juan Xiao; Ping Zheng; Lei Zhong; Qian Peng
Journal:  World J Gastrointest Oncol       Date:  2022-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.